MedTrace Logo

A Phase 1 Clinical Study in Healthy Participants

NCT07584876 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-13

No results posted yet for this study

Summary

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-41012 in Healthy Participants

Conditions

  • HV

Interventions

DRUG

BW-40202 injection or Placebo

BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection

DRUG

BW-40202 injection or Placebo

BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection

DRUG

BW-40202 injection or Placebo

BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection

DRUG

BW-40202 injection or Placebo

BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection

DRUG

BW-40202 injection or Placebo

BW-40202 injection or Placebo dosage form is solution for injection and route of administration is subcutaneous injection

Sponsors & Collaborators

  • Shanghai Argo Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2027-10-30
Completion
2028-01-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07584876 on ClinicalTrials.gov